Haemonetics Q2 Fiscal 2023 Earnings Release Available on Investor Relations Website

0

Financial press release available online

BOSTON, November 7, 2022 /PRNewswire/ — Haemonetics Corporation (NYSE: HAE) announced that financial results for its second quarter of fiscal 2023, which ended October 1, 2022are available on its Investor Relations website.

The Company will host a conference call and webcast with investors and analysts to discuss and answer questions about the results to 8:00 a.m. ET on November 7, 2022. The conference call and webcast can be accessed with the following information:

In addition, the Company has posted on its Investor Relations website the earnings release and analytical tables and additional information that will be referenced during its conference call and webcast, the direct links of which are available below. below.

Direct link to Publication of the results of the 2nd quarter of the financial year 23:
https://haemonetics.gcs-web.com/static-files/f7bd49f3-53f3-412d-9e2f-a8793baa052b

Direct link to 2Q FY23 analytical tables and additional information:
https://haemonetics.gcs-web.com/static-files/f02bd23c-d80b-491e-ab3a-f299118c93f3

A replay of the conference call and webcast will be available for one year from November 7, 2022at 11:00 a.m. ET using the conference call webcast link provided in this press release.

About hemonetics
Haemonetics (NYSE:HAE) is a global healthcare company dedicated to providing a suite of innovative medical products and solutions to its customers to help them improve patient care and reduce the cost of healthcare. health. Our technology is aimed at important medical markets: the collection of blood and plasma components, the operating room and hospital transfusion services. To learn more about Haemonetics, visit www.haemonetics.com.

Investor contacts:


Olga Guyette, Senior Director, Investor Relations and Treasury

David Trenk, Head of Investor Relations

(781) 356-9763

203) 733-4987

[email protected]

[email protected]



Media Contact:


Josh Gitelson, Director of Global Communications


(781) 356-9776


[email protected]


SOURCEHaemonetics Corporation

Share.

Comments are closed.